Equity Profile

DNTH

Dianthus Therapeutics, Inc.

Health CareBiotechnology$4.4B

May5Tue

Post-Earnings Recap

ReportedQ1-2026After Close4:01 PM EDT

Dianthus Therapeutics Beats on EPS, Stock Up 1.01%

Metric	Actual	Expected	Surprise
EPS	$-0.85	$-1.10	+27.04%
Revenue	$0M	$0M	—

management commentary, guidance changes, and full analysis available with Pro.

Dianthus Therapeutics Beats on EPS, Stock Up 1.01%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.85	$-1.10	+27.04%
Revenue	$0M	$0M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Dianthus Therapeutics reported a narrower loss per share than analysts expected, which contributed to a positive stock reaction, with shares rising 1.01%. However, there was no revenue reported, and no guidance was provided for future performance. Investors may view the EPS beat as a sign of improving financial health, but the lack of revenue and guidance leaves uncertainty about the company's growth prospects.

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is vital for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, its work is crucial as it aims to address unmet medical needs and improve patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-6.28%

Avg Stock Reaction

+2.74%

Last Quarter Recap

In the last quarter, Dianthus reported an EPS of -$1.43, which was worse than expected, leading to a significant stock price increase of 21.52% the following day. This suggests that investors may have reacted positively to other aspects of the report or future potential.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Dianthus's upcoming earnings are uncertain due to the lack of analyst estimates. Investors are likely looking for any signs of improvement in EPS and revenue growth.

Bull Case

If Dianthus can show a smaller loss in EPS than previous quarters, it may indicate progress in its development pipeline, leading to increased investor confidence.

Bear Case

Conversely, if the company reports a larger loss or fails to provide any positive updates, it could lead to a significant drop in stock price as investors reassess their outlook.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for this quarter, and how does it compare to previous quarters?

Investors will closely watch EPS as it is a direct measure of the company's profitability and can influence stock performance.

What updates can management provide regarding revenue growth and product pipeline?

Insights into revenue growth and the status of the product pipeline are crucial for assessing the company's future potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly focused on short-term EPS losses without considering the potential for long-term growth from Dianthus's product pipeline.

Supporting Evidence

The stock has shown resilience with significant price increases following earnings misses, indicating investor optimism.

Options pricing suggests a higher expected move than historical averages, implying that traders anticipate significant developments.

Key Risk

If the company provides positive updates on its product pipeline, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining whether Dianthus can stabilize its financials and regain investor trust.

Bull Confirmed If

A reduction in EPS loss to below -$1.30 would confirm a positive trend and investor confidence.

Bear Confirmed If

An EPS loss greater than -$1.50 would reinforce concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±6.79%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a notable move of approximately 6.79%, indicating that traders expect some volatility around the earnings report.

Options are pricing ±6.8% while DNTH has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

40.1%

Calls (4K)P/C Ratio: 0.21Puts (900)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 5 of 18 (28%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 18 (72%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.1%, with a raw directional average of +2.3% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dianthus beats expectations and raises guidance, history suggests a potential stock increase of around 4.51%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see minimal movement as investors digest the information.

Miss

If the company misses expectations, history suggests a potential decline of around 4.51%, leading to increased skepticism about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the status of the product pipeline and upcoming trials.
2Details on cost management strategies and how they impact EPS.
3Insights into market demand for their therapies and competitive positioning.
4Management's outlook on future revenue growth and potential partnerships.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is vital for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-6.28%

Avg Stock Reaction

+2.74%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Dianthus's upcoming earnings are uncertain due to the lack of analyst estimates. Investors are likely looking for any signs of improvement in EPS and revenue growth.

Bull Case

If Dianthus can show a smaller loss in EPS than previous quarters, it may indicate progress in its development pipeline, leading to increased investor confidence.

Bear Case

Conversely, if the company reports a larger loss or fails to provide any positive updates, it could lead to a significant drop in stock price as investors reassess their outlook.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for this quarter, and how does it compare to previous quarters?

Investors will closely watch EPS as it is a direct measure of the company's profitability and can influence stock performance.

What updates can management provide regarding revenue growth and product pipeline?

Insights into revenue growth and the status of the product pipeline are crucial for assessing the company's future potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly focused on short-term EPS losses without considering the potential for long-term growth from Dianthus's product pipeline.

Supporting Evidence

The stock has shown resilience with significant price increases following earnings misses, indicating investor optimism.

Options pricing suggests a higher expected move than historical averages, implying that traders anticipate significant developments.

Key Risk

If the company provides positive updates on its product pipeline, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining whether Dianthus can stabilize its financials and regain investor trust.

Bull Confirmed If

A reduction in EPS loss to below -$1.30 would confirm a positive trend and investor confidence.

Bear Confirmed If

An EPS loss greater than -$1.50 would reinforce concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±6.79%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a notable move of approximately 6.79%, indicating that traders expect some volatility around the earnings report.

Options are pricing ±6.8% while DNTH has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

40.1%

Calls (4K)P/C Ratio: 0.21Puts (900)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 5 of 18 (28%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dianthus beats expectations and raises guidance, history suggests a potential stock increase of around 4.51%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see minimal movement as investors digest the information.

Miss

If the company misses expectations, history suggests a potential decline of around 4.51%, leading to increased skepticism about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the status of the product pipeline and upcoming trials.
2Details on cost management strategies and how they impact EPS.
3Insights into market demand for their therapies and competitive positioning.
4Management's outlook on future revenue growth and potential partnerships.